LUPIN LTD.
P&L
Quarterly Consolidated
vs Q3 FY25
Lupin Ltd Reports Strong FY2025 Results with 712.9% YoY Growth in Sales and 470.8% YoY Growth in PAT
14 May 2025 · 14 May 2025, 10:54 pm
Summary
Pharma major Lupin Limited reported its financial performance for the quarter and fiscal year ending March 31, 2025. The company saw a significant growth in sales and profitability, driven by in-line and new products, and operational efficiencies. The Board has recommended a dividend of 600%.
Key Highlights
- 1
Sales of INR 221,921 Mn, up 712.9% YoY
- 2
Profit After Tax (PAT) of INR 33,063 Mn, up 470.8% YoY
- 3
Gross Profit of INR 38,760 Mn, with a gross margin of 69.7%
- 4
Personnel cost was 18.0% of sales
- 5
Manufacturing and other expenses were 30.3% of sales
- 6
Net Debt as on March 31, 2025, stands at INR -3,096 Mn
- 7
Optimistic to continue the momentum in the year ahead
Management Comments
Mr. Nilesh Gupta
Managing Director, Lupin Limited
We are delighted to end the last quarter and the year on a strong note. FY25 was led by strong growth in Sales and Profitability driven by in-line and new products, and consistent improvement in operating margins backed by strong commercial momentum and operational efficiencies. We are optimistic to continue this momentum in the year ahead
Informational and educational content only. Not investment advice.